Current and historical daily PE Ratio for Acerus Pharmaceuticals Corp (
) from 2009 to Jun 16 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Acerus Pharmaceuticals stock (TSX:ASP) PE ratio as of Jun 16 2024 is 0.
More Details
Acerus Pharmaceuticals Corp (TSX:ASP) PE Ratio (TTM) Chart
Acerus Pharmaceuticals Corp (TSX:ASP) PE Ratio (TTM) Historical Data
View and export this data going back to 2009. Start your Free Trial
Total 959
- 1
- 2
- 3
- 4
- 5
- 6
- 11
| Acerus Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-16 | At Loss | 2023-01-02 | At Loss |
| 2023-03-03 | At Loss | 2022-12-30 | At Loss |
| 2023-03-02 | At Loss | 2022-12-29 | At Loss |
| 2023-03-01 | At Loss | 2022-12-28 | At Loss |
| 2023-02-28 | At Loss | 2022-12-23 | At Loss |
| 2023-02-27 | At Loss | 2022-12-22 | At Loss |
| 2023-02-24 | At Loss | 2022-12-21 | At Loss |
| 2023-02-23 | At Loss | 2022-12-20 | At Loss |
| 2023-02-22 | At Loss | 2022-12-19 | At Loss |
| 2023-02-21 | At Loss | 2022-12-16 | At Loss |
| 2023-02-20 | At Loss | 2022-12-15 | At Loss |
| 2023-02-17 | At Loss | 2022-12-14 | At Loss |
| 2023-02-16 | At Loss | 2022-12-13 | At Loss |
| 2023-02-15 | At Loss | 2022-12-12 | At Loss |
| 2023-02-14 | At Loss | 2022-12-09 | At Loss |
| 2023-02-13 | At Loss | 2022-12-08 | At Loss |
| 2023-02-10 | At Loss | 2022-12-07 | At Loss |
| 2023-02-09 | At Loss | 2022-12-06 | At Loss |
| 2023-02-08 | At Loss | 2022-12-05 | At Loss |
| 2023-02-07 | At Loss | 2022-12-02 | At Loss |
| 2023-02-06 | At Loss | 2022-12-01 | At Loss |
| 2023-02-03 | At Loss | 2022-11-30 | At Loss |
| 2023-02-02 | At Loss | 2022-11-29 | At Loss |
| 2023-02-01 | At Loss | 2022-11-28 | At Loss |
| 2023-01-31 | At Loss | 2022-11-25 | At Loss |
| 2023-01-30 | At Loss | 2022-11-24 | At Loss |
| 2023-01-27 | At Loss | 2022-11-23 | At Loss |
| 2023-01-26 | At Loss | 2022-11-22 | At Loss |
| 2023-01-25 | At Loss | 2022-11-21 | At Loss |
| 2023-01-24 | At Loss | 2022-11-18 | At Loss |
| 2023-01-23 | At Loss | 2022-11-17 | At Loss |
| 2023-01-20 | At Loss | 2022-11-16 | At Loss |
| 2023-01-19 | At Loss | 2022-11-15 | At Loss |
| 2023-01-18 | At Loss | 2022-11-14 | At Loss |
| 2023-01-17 | At Loss | 2022-11-11 | At Loss |
| 2023-01-16 | At Loss | 2022-11-10 | At Loss |
| 2023-01-13 | At Loss | 2022-11-09 | At Loss |
| 2023-01-12 | At Loss | 2022-11-08 | At Loss |
| 2023-01-11 | At Loss | 2022-11-07 | At Loss |
| 2023-01-10 | At Loss | 2022-11-04 | At Loss |
| 2023-01-09 | At Loss | 2022-11-03 | At Loss |
| 2023-01-06 | At Loss | 2022-11-02 | At Loss |
| 2023-01-05 | At Loss | 2022-11-01 | At Loss |
| 2023-01-04 | At Loss | 2022-10-31 | At Loss |
| 2023-01-03 | At Loss | 2022-10-28 | At Loss |
Acerus Pharmaceuticals Corp (TSX:ASP) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Acerus Pharmaceuticals Corp
NAICS : 325412
SIC : 3741
ISIN : CA00444G1081
Compare
Compare
Traded in other countries / regions
ASP.Canada3TP0.Germany IPO Date
2009-09-03Description
Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers